To Tackle High Drug Prices, Tear Down the Rebate Wall

In a period of deep political polarization, politicians on both sides of the aisle agree that Americans are paying too much for pharmaceutical drugs. During the 2020 presidential election, both Joe Biden and Donald Trump made lowering drug prices a central pillar of their respective campaigns, suggesting in the next four years there could be […]

BLOCKING Act Would Delay Patient Access to Cheaper Prescription Drugs

The Following is a statement from Krisztina Pusok, Director of Policy and Research at ACI: “ACI strongly supports Congressional efforts seeking to lower prescription drug prices for patients, consumers, and taxpayers. Unfortunately, the “Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act,” would achieve the exact opposite of what it is […]

Letter to the President: Don’t Restrict the Supply Chain for Drugs or Medical Devices

Today, a group of 68 nonprofits and associations sent a letter to the President cautioning him against any executive actions that may restrict access to or destabilize the supply chain for pharmaceuticals or medical devices. At this time, while supply chains for a broad range of U.S. industries are stressed due to the global COVID-19 […]

ACI Joins Coalition in Opposition to the Pelosi Drug Tax Pan

Today, ACI joined 70 other organizations in opposition to the prescription drug pricing bill offered by House Speaker Nancy Pelosi. The bill would impose excise taxes up to 95% on hundreds of prescription medicines. You can read the coalition letter online. 10-15-19 Coalition Letter Opposed to Pelosi Drug Tax Plan

Real Clear Health: Drug Importation — High Risk, Low Reward

It’s tempting to think that legalizing drug importation would immediately give U.S. consumers access to medicines at the prices available in other developed countries. In reality, however, the Safe Importation Action Plan would expose American consumers to significant health risks while achieving meager cost reductions, if any at all. Visit Real Clear Health to lean […]

Townhall: Importing Drugs from Canada Would Kill Innovation and Could Cost Lives

In partnership with the Food and Drug Administration (FDA), the Department of Health and Human Services (HHS) has recently proposed that certain pharmaceuticals should be cleared for import from Canada. Although the proposal seeks to lower prices for consumers, it poses critical unintended risks to both American businesses and patients. To read why, visit Townhall.

Open the Canadian Border for Drug Imports, and Dangerous Counterfeits will Follow

In an effort to reverse the continuing rise of prescription drug prices, the Food and Drug Administration (FDA) and the Department of Health and Human Services (DHHS) are mulling the idea of allowing drug imports from Canada. Their so-called “Safe Importation Action Plan,” however, is a misnomer—the policy could expose countless Americans to potentially deadly […]

Biosimilars: The Grand Experiment

Biosimilars are the grand experiment. If the biosimilar experiment succeeds, competition will lead to lower prices and increase access for patients. However, if biosimilar competition does not advance the result may be price controls. This could decrease the incentive to innovate and lead to fewer new drugs being developed. Biologics are among the highest priced […]